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ABSTRACT
Background. A better assessment of individualized prostate
cancer (PrCa) risk is needed to improve screening. The use of
the prostate-specific antigen (PSA) level for screening in the
generalpopulationhas limitationsand isnotcurrentlyadvocated.
Approximately 100 common single nucleotide polymorphisms
(SNPs) have been identified that are associated with the risk of
developing PrCa.The PROFILE pilot study explored the feasibility
of using SNP profiling inmenwith a family history (FH) of PrCa to
investigate the probability of detecting PrCa at prostate biopsy
(PB). The primary aim of this pilot study was to determine the
safety and feasibility of PrCa screening using transrectal
ultrasound-guided PB with or without diffusion-weighted
magnetic resonance imaging (DW-MRI) in men with a FH. A
secondary aim was to evaluate the potential use of SNP
profiling as a screening tool in this population.
Patients and Methods. A total of 100 men aged 40–69 years
with a FH of PrCa underwent PB, regardless of their baseline
PSA level. Polygenic risk scores (PRSs)were calculated for each
participant using 71 common PrCa susceptibility alleles. We
treated thediseaseoutcomeatPBas theoutcomevariableand
evaluated its associationswith thePRS, PSA level, andDW-MRI
findings using univariate logistic regression.
Results. Of the 100 men, 25 were diagnosed with PrCa, of
whom 12 (48%) had clinically significant disease. Four adverse
events occurred and no deaths.The PSA level and age at study
entry were associated with PrCa at PB (p 5 .00037 and p 5
.00004, respectively).
Conclusion.The results of the present pilot study have demon-
strated that PB is a feasible and safemethodof PrCa screening in
menwithaFH,withahighproportionofPrCa identifiedrequiring
radical treatment. It is feasibletocollectdataonPrCa-riskSNPsto
evaluate their combined effect as a potential screening tool. A
larger prospective study powered to detect statistical associa-
tions is in progress.The Oncologist 2016;21:716–722
Implications for Practice: Prostate biopsy is a feasible and safe approach to prostate cancer screening inmenwith a family history
and detects a high proportion of prostate cancer that needs radical treatment. Calculating a polygenic risk score using prostate
cancer risk single nucleotide polymorphisms could be a potential future screening tool for prostate cancer.
INTRODUCTION
Prostate cancer (PrCa) is the most common cancer in men in
Europe and constitutes a significant health burden. Screening
for PrCa in the general population using the prostate-specific
antigen (PSA) level is controversial and not currently advocated
owing to its inability to distinguish between clinically significant
and indolent disease and conflicting evidence on the effect on
mortality [1–3]. Overdiagnosis and overtreatment are signifi-
cant limitations of PSA screening. However, targeted screening
aimed at higher risk groups might have a greater impact [4].
Excluding age and African-American ancestry, the strongest risk
factor for PrCa is a family history (FH) [5]. First-degree relatives
(FDRs)ofmenwithPrCahaveapproximately twicetheriskofthe
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general population, which increases to more than fourfold if
PrCa was diagnosed in a relative when he was younger than
60 years [6]. Several germline single nucleotide polymorphisms
(SNPs) have been associated with PrCa risk [5]. Although the
effect of each of these variants is small, they actmultiplicatively
and togetherexplain∼30%of thegenetic varianceofPrCa [5].
Several studies have reported that polygenic risk scores
(PRSs), based on the combined effects of these SNPs, could
be used to predict a man’s future PrCa risk [6, 7] and could
be useful for targeted screening. However, it is unclear how
they relate to the probability of detecting existing PrCa in
asymptomatic men.
In the present cross-sectional pilot study, the primary aim
wastodetermine the feasibilityofusingprostatebiopsy (PB) as
a screening tool (irrespective of the PSA level) inmenwith a FH
of PrCa.The secondary aims were to evaluate the feasibility of
collectingdataonSNPprofiles,PSAlevels,anddiffusion-weighted
magnetic resonance imaging (DW-MRI) and assesswhether they
could be used as screening tools in this population.
PATIENTS AND METHODS
Patients
Eligible men were identified as follows: (a) through cancer
genetics and uro-oncology clinics at a National Health Service
cancer hospital in London; (b) men taking part in the U.K.
Genetic Prostate Cancer study (UKGPCS; http://www.icr.ac.
uk/ukgpcs); and (c) advertisements and newsletters. For the
first two methods, men with PrCa were approached either in
clinic or by letter and invited topass onan information sheet to
eligible relatives. The eligibility criteria included (a) age 40–69
years; (b) a FHof PrCa; (c) if previous PBhadbeenperformed, it
must have been performed$1 year earlier; and (d) provision
of informed consent. Men with a previous diagnosis of PrCa,
currently undergoing evaluations for symptoms suggestive of
PrCa,ordiagnosedwithcancerwitha terminal prognosisof,5
years were excluded. A FH was defined as having (a) one FDR
with PrCa diagnosed at,70 years; (b) two relatives (FDRs or
second-degree relatives) on the same side of the familywith at
least one diagnosed at age,70 years; or (c) three relatives on
the same side of the family diagnosed at any age.
Study Design
After providing written informed consent, the participants
completed a family and medical history questionnaire and
provided blood samples for PSA measurement and DNA
extraction. All men underwent a 10-core (standard practice at
the time the protocol was written) transrectal ultrasound-
guided PB, regardless of the baseline PSA level, within 8weeks
of study entry. Standard antibiotic prophylaxis was used, and
the biopsies were performed to a standard template by two
urologists (N.B., P.K.). An expert pathologist reviewed all of the
biopsy specimens (S.H.). The participants who rejected an
initial PB were followed up with 6-month PSA measurements
and were excluded from the present analyses. The study
algorithm is detailed in Figure 1.
The first 50 patients enrolled in the direct biopsy armwere
also offered DW-MRI before biopsy [8]. The images were
assessed by an experienced observer using a combination of
T2-weightedandDWimages and scoredaspositiveor negative
for tumor. This was not used to guide the biopsy, because this
component of the study was to gauge the acceptability of this
technique to inform the future main study design. The results of
this component of the study have been reported separately [8].
For those patients diagnosed with PrCa at PB, management
was offered either at the cancer center or at their local hospital
according to the standard U.K. national guidelines [9]. The
outcomes of the different treatments for these patients will be
followed up for 5 years. Those patients who presented with
atypical small acinar proliferation (ASAP) or high-grade prostatic
intraepithelialneoplasia (HG-PIN)underwentrepeatbiopsyafter
6 months. Men with negative biopsy findings were monitored
with PSA testing every 6months, with the biopsy repeated if the
PSA level increased by.50% (data not presented).
Genetic Profiling
The participants’ DNA samples were genotyped using a
custom Illumina iSelect genotyping array [10, 11].We used
the data for 71 known PrCa susceptibility SNPs; 61 were di-
rectly genotyped and, for 10 loci, the data for a proxy SNP with
pairwise correlation of r2 . 0.75 were used (supplemental
online Table 1).
Statistical Analysis
For each patient, the PRS was calculated as the weighted sum
of thenumberof riskallelesat the71 loci, forwhich theweights
were the estimated log-odds ratios (ORs) associatedwith each
allele, obtained from published studies [5]. In an exploratory
analysis, we used univariate logistic regression to evaluate the
associationsofageat studyentry,PSA,andPRSwithadiagnosis
of PrCa at PB. R, version 3.1.2 (October 31, 2014), was used for
statistical analysis [12].
RESULTS
FromDecember 2010, 897men aged 40–69 years with a FH of
PrCa were invited into the study, and 285 (32%) replied. The
enrollment was closed in January 2013 when 115 men had
entered the study and 100had agreed to undergo PB (Table 1).
SixmenhadpreviouslyundergonePBatameanof45.3months
(range 24–96). Fifteenmen declined PB and were followed up
with PSA measurements only and were excluded from the
present analyses.
The median age of the participants was 53 years (range
40–69), with a median PSA level of 1.3 ng/mL (range 0.2–9.8;
Table 2). Ten-core PB identified 7 cases of HG-PIN, 5 cases of
ASAP, and 25 cases of PrCa. The median age of PrCa diagnosis
was61 years (range 44–69),withmedianPSA level of 2.7 ng/mL
(range 0.35–9.3). The median age of men diagnosed with
PrCawasolder than thatof thosewithnegativebiopsy findings
(61 vs. 50 years; p5 .00004). No differenceswere found in the
rates of cancer diagnosis between the men according to their
family history (Table 3). Thirteen tumors were low-risk (52%),
10 were intermediate-risk (40%), and 2 (8%) were high-risk as
classified by the National Institute for Health and Care
Excellence (NICE) criteria [9] (Table 4).
Complications occurred in 4 of the 100 participants (4%),
with 3 postbiopsy infections (3%) reported and treated with a
course of oral (n5 2) or intravenous (n5 1) antibiotics. One
patient (1%) was kept under observation because he had
fainted after the biopsy.
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Univariate association analyses showed that the PSA level
was associated with the PrCa diagnosis (OR 1.73, 95% CI
1.28–2.33; p 5 .00037). Age at study entry was also
significant (OR 1.16, 95% CI 1.08–1.25; p 5 .00004);
however, we found no significant association between the
PRS and PB outcome (p5 .25802; Fig. 2).When stratified by
the Gleason score of the tumor (7 or greater vs. less than 7),
no association was observed between the PRS and tumors
with a Gleason score of 7 or greater (p 5 .21057). The PSA
levelwas associatedwith a highGleason score (OR1.85, 95%
CI 1.13–3.03; p5 .01456).
Wealso evaluated the association between the PRS for the
different levels of the presenting PSA. The PRS did not differ
betweenmenfoundtohaveprostatecancerandthosewithout
Figure 1. PROFILE study algorithm.
Abbreviations: ASAP, atypical small acinar proliferation; DW-MRI, diffusion-weightedmagnetic resonance imaging; FDR, first-degree
relative; HGPIN, high-gradeprostatic intraepithelial neoplasia; PrCa, prostate cancer; PSA, prostate-specific antigen; SDR, second-degree
relative; SNPs, single nucleotide polymorphisms.
©AlphaMed Press 2016
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thediseaseafterbiopsyamongmenwithaPSA level,3ng/mL
(p 5 .15) or PSA level ,1 ng/mL (p 5 .08). This group
constituted 38menwith 5 PrCas diagnosed; themedian age at
PrCa diagnosis was 57 years (range 44–69).
All patients diagnosed with low-risk PrCa opted for active
surveillance. For those choosing radical treatment, radical
prostatectomy was chosen by 10 men (40%). One patient
underwent radiotherapywithCyberKnife (Accuray, Sunnyvale,
CA, http://www.cyberknife.com), and one patient with
metastatic disease received hormonal treatment alone.
DISCUSSION
The present study was undertaken to assess the feasibility of
using primary PB in a known higher risk group without the
confounder of the PSA level used to trigger biopsy.The reason
for undertaking the present study was to be able to inform a
larger PROFILE study, which will be powered to be able to
associate the PRS outcome with the PB outcome. A FH group
was chosen because this increased the power approximately
fourfold.These results provide evidence that it is feasible to
screen for PrCa using upfront PB in men with a FH of the
disease, and approximately one third of men will agree to
such screening. Of the men undergoing PB, 25% were
diagnosed with PrCa, of whom 48% had disease that was
intermediate- or high-risk and warranting treatment using
the NICE guidelines.
Interestingly, of the 25 study participants diagnosed with
PrCa, 13 (52%) had a PSA level,3 ng/mL, and these patients
wouldmost likelyhavenotundergonePBwithin the traditional
PSA-based screening schedules. This is a finding that raises
questionsabout the reliabilityofPSAdetermination, especially
for men with a significant FH. In contrast, the Prostate Cancer
Prevention Trial (PCPT) reported anoverall PrCa detection rate
of 15.2% in 2,950 men with a PSA level ,4.0 ng/mL and
unsuspicious digital rectal examination findings. They found
that only 19.6%of tumors hadhigh-gradedisease (defined as a
Gleason score.7), and themenwere older, with an age range
of 62–91 years [13]. Although the two studies are not directly
comparable because of the different classifications of disease
risk and different PSA levels used, a remarkable differencewas
found in the proportion of clinically significant tumors. Larger
studies are required to confirm thedifferences observed. Little
is known about the effect of FH on PrCa progression and the
benefits of early diagnosis in this group [14]. All but one man
diagnosed with low-risk PrCa accepted active surveillance,
highlighting the growing understanding of the natural history
of PrCa and the increasing acceptance of a structured moni-
toring strategy.
Another major concern with using PB for PrCa screening is
safety. Although hematuria and hematospermia are common,
severe postprocedural infections have been reported to occur
in approximately 1% of cases, with major complications rare
[15]. A similar incidence was observed in our series, with a 4%
infection rate, 1% requiring hospitalization, and no major
complications reported. Therefore, the potential negative
consequences of PrCa screening, including biopsy complica-
tions and cancer diagnosis, were regarded as acceptable for
proceeding to themain study, whichwill be powered to detect
the effect of the PRS in the screening algorithm. Men in the
PROFILE study might be more predisposed to accept more
screening-related side effects than the general population
owing to their previous experience of relatives developing
PrCa. However, a recent study evaluating the psychological
effect of prostate biopsy in 1,147menwho had participated in
the Prostate Testing for Cancer and Treatment (ProtecT) trial
reported that postbiopsy symptoms such as discomfort, pain,
or bleeding were experienced relatively commonly and for
most patients were tolerated as a minor problem or no
problem [16].
In the present pilot study, we performed exploratory
analyses to assess the performance of age, PSA level, and PrCa
risk SNPs in predicting the biopsy outcome in this setting. It is
important to note that the SNP risk scores and PSA level were
considered in our study as tools for predicting the PB outcome
Table 1. Responses of men invited into the study
Description n (%)
Total men invited 897 (100.0)
Did not reply 612 (68.2)
Replied 285 (31.8)
Declined 85 (9.5)
Accepted 115 (12.8)
Accepted but ineligible 31 (3.5)
Expressed an interest 47 (5.2)
Would take part if available locally 7 (0.8)
Table 2. Age at study entry, PSA level, and polygenic risk score
Variable
Prostate
cancer Mean Median Range (SD)
Age at study
entry
No 51.2 50.2 40.3–67.3 (7.6)
Yes 59.9 60.9 44.6–68.5 (6.8)
BaselinePSA No 1.4 1.1 0.19–9.8 (1.35)
Yes 3.4 2.7 0.52–9.3 (2.54)
Polygenic
risk score
No 0.1 0.1 0.023–0.222 (0.039)
Yes 0.1 0.1 0.041–0.156 (0.033)
Abbreviation: PSA, prostate-specific antigen.
Table 3. Family history of prostate cancer
Variable %
Total cohort, n5 100
One FDR with PrCa diagnosed at age,70 yr 36
Two relatives (FDR or SDR) on same side of family;
one diagnosed at age,70 yr
37
Three relatives on same side of the family
diagnosed at any age
27
PrCa cases, n5 25
One FDR with PrCa diagnosed at age,70 yr 36
Two relatives (FDR or SDR) on same side of the family;
one diagnosed at age,70 yr
40
Three relatives on same side of the family diagnosed
at any age
24
Abbreviations: FDR, first-degree relative; PrCa, prostate cancer; SDR,
second-degree relative.
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rather than predicting the future risk of developing PrCa. The
latter could not be evaluated in the present study design;
however, as prospective data are accumulated, it will be
assessed in the future.
In the present small pilot study using univariate analyses,
the SNP profile was not associated with prostate cancer at PB,
although theestimatedORwasgreater than1.However,much
larger studies are required to address this question reliably.
Table 4. Characteristics of prostate cancers diagnosed in the study
Age at diagnosis (yr) PSA at diagnosis (ng/mL) Gleason score Stage Treatment Risk of relapse PRSa
62 17.2 413 T3N0 LHRH agonist High 0.04
54 7.9 413 pT3 Prostatectomy High 0.07
68 4.6 314 T2N0 Prostatectomy Intermediate 0.09
60 5.7 313 T2c CyberKnife Intermediate 0.12
68 5.2 314 pT2a Prostatectomy Intermediate 0.10
67 3.2 314 pT2c Prostatectomy Intermediate 0.06
55 5.4 313 pT2c Prostatectomy Intermediate 0.11
68 9.3 314 pT2c Prostatectomy Intermediate 0.10
69 0.35 313 pT2c Prostatectomy Intermediate 0.13
57 2.7 314 pT2c Prostatectomy Intermediate 0.15
56 8 314 pT2c Prostatectomy Intermediate 0.10
67 5.7 314 pT2c Prostatectomy Intermediate 0.05
61 0.97 313 T1b Active surveillance Low 0.12
44 0.52 313 T1b Active surveillance Low 0.12
51 0.74 313 T1c Active surveillance Low 0.11
52 1.2 313 T1c Active surveillance Low 0.11
57 1.1 313 T1c Active surveillance Low 0.07
55 0.87 313 T1c Active surveillance Low 0.06
66 1.6 313 T1c Active surveillance Low 0.05
67 4.5 313 T1c Active surveillance Low 0.05
63 1.8 313 T1c Active surveillance Low 0.08
66 1.3 313 T1c Active surveillance Low 0.16
61 2.5 313 T1c Active surveillance Low 0.11
49 2.8 313 T1c Active surveillance Low 0.13
63 4 313 T1c Active surveillance Low 0.10
aRisk of developing prostate cancer by 85 years old.
Abbreviations: LHRH, luteinizing hormone-releasing hormone; PRS, polygenic risk score; PSA, prostate-specific antigen.
Figure 2. The distribution of PRSs in the cohort. No significant association was found between the PRS and the prostate biopsy outcome
(p5 .25802).
Abbreviations: PrCa, prostate cancer; PRS, polygenic risk score.
©AlphaMed Press 2016
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Furthermore, this might be improved as further common
variants are identified, which will increase the discrimination
of the risk strata in populations. A possible confounder that
mighthave caused this is that themen in thepresent studyhad
a strong FH and their genetic risk was high, resulting in poor
discrimination. Analyses of larger series of participants with
adjustment for all relevant confounders are therefore
warranted. Others have previously reported similar results,
with areas under the curve that ranged from 0.57 to 0.67,
although their prediction models included fewer genetic
variants than did ours [7, 17–20].
The predictive value of SNP profiling in men presenting
with a PSA level of 1–3 ng/mL was assessed by Nordstro¨m
et al. [21], who found that a risk score based on 49 SNPswas a
significant predictor of positive biopsy findings (p 5 .028).
Based on current clinical practice, if these men were mon-
itored using a PSA screening protocol, they would not
undergo PB. In the PROFILE study, we analyzed the predictive
value of the genetic score for men with a FH and a very low
presenting PSA level of #1 ng/mL. These men would have
normally been reassured by the PSA result, and we found no
significant association between the PRS and PrCa diagnosis.
However, the number of PrCas diagnosed in asymptomatic
young men with a very low PSA level was sizeable (13% had
PrCa at PB).
SNP profiling is an important tool in PrCa risk prediction
algorithms. Risk predictionmodels serve to identify thosemen
who could potentially benefit from screening, through early
diagnosis and treatment [22]. Namet al. reported a prediction
model using FH, PSA level, and four of the published genome-
wide association study (GWAS) risk SNPs, which improved the
positive predictive value of the PSA level [18]. Zheng et al.
included 11 SNPs in their model and showed that the
prediction of the combination of genetic variants and FH was
similar to thatof thePSA level [23].Pashayanetal. reportedthe
use of a polygenic risk model to personalize screening and
compared this with a theoretical model in which only age was
used to determine whether to screen a population [24]. They
showed that the use of SNPs reduced the risk of an
overdiagnosis [24]. Macinnis et al. developed a model for
predicting the probability of developing PrCa in the future
using 26 SNPs and FH [25]. Kader et al. developed a
multivariablepredictivemodel forpatientswhohadpreviously
hadnegativePB findings [7].Thepredictiveperformanceof the
model, which included age, FH, PSA, prostate volume, and
number of cores at PB, was improved after the addition of the
genetic score based on 33 PrCa risk-associated SNPs. The
proposed PROFILE study offers a unique opportunity to
prospectively determine the benefit of the model, as the
participants will be followed up for 5 years.
We acknowledge that the present pilot study had several
weaknesses. The PROFILE study was designed as a feasibility
study and, therefore, had a small sample size that did not allow
definitive conclusions.Therefore, we did not test the ability of
the genetic score to distinguish between the risk of indolent
versus aggressive disease. Debate has ensued whether the
SNPs identified to date are able to distinguish between these
two forms of PrCa [26]. Second, most SNPs were selected by
their association with a lifetime risk of developing prostate
cancer, rather than predicting cancer at any given time.
Therefore, a prospective study with long-term follow-up is
necessary to provide the data required to evaluate their use in
a predictive risk model. Third, the present analysis only
included men of European ancestry, because several GWASs
included only men of this ethnicity, and it is not clear to what
extent these results are applicable to other ethnic groups.
Furthermore, all men had a FH of PrCa and, therefore, an
increased risk of PrCa compared with the general population,
whichmighthavemadethemmorereceptive toundergoingPB
and might also explain the high incidence of PrCa and pre-
cancerous findings in thepresentseries.Moreover,bydefinition,
all the participants in the present study were expected to have
higherPRSscomparedwith thegeneralpopulation,whichwould
limit the ability of the PRS to discriminate between those with
PrCa at PB and those without PrCa.
The main PROFILE study started recruiting in 2015, with
the aim of recruiting 350 men of European ancestry with a FH
and350menofAfrican-Caribbean ancestry. In addition toDW-
MRI, other predictive biomarkerswill be incorporated, such as
urinary PCA3andTMPRSS-ERG translocation status.Weaim to
use the most up-to-date SNP set available to calculate the risk
score by ethnic group.
CONCLUSION
PROFILE is the first studyconductedofmenwithaFHofPrCa to
incorporate biopsy, genetic profiling, imaging, and biomarkers
in an innovative screeningmodel.The feasibility studywehave
reported showed that one quarter of themenwho underwent
a PB were found to have PrCa, and 48% of these had disease
that required radical treatment using the NICE guidelines. Our
results indicatethatdirectPB is feasibleandsafeasamethodof
PrCa screening in men with an FH of PrCa. A larger study is
underway for the development of a prediction model com-
bining clinical variables and PrCa risk-associated SNPs that
would help to determine whichmen at high risk of PrCa owing
to their FH of PrCa should undergo PB.
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